Background: The BASIL investigators reported that overall survival and amputation-free survival were not different at 2-year after endovascular therapy (EVT)-first or bypass surgery (BSX)-first revascularization strategies for patients with critical limb ischemia (CLI). However, beyond 2 years there appeared to be a benefit for BSX. methods: Between January 2007 and December 2011, 459 consecutive patients with CLI who underwent first EVT (396 patients) or BSX (63 patients) were enrolled, and assigned to two groups; alive at > 2-year or dead within 2-year. Multivariate analysis was performed to explore independent mortality determinants and risk stratification.
